162 related articles for article (PubMed ID: 35049019)
41. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
Kimpton M; Carrier M
Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842
[TBL] [Abstract][Full Text] [Related]
43. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson CM; Finks SW
Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
[TBL] [Abstract][Full Text] [Related]
44. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
van Es N; Büller HR
Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
46. Management of antithrombotic therapy in gray areas of venous thromboembolism: a Delphi consensus panel.
Barillari G; Bortoluzzi C; Giorgi M; Orabona R; Pacetti E; Sciatti E; Zaffaroni M; Dentali F
Intern Emerg Med; 2020 Oct; 15(7):1255-1264. PubMed ID: 32232785
[TBL] [Abstract][Full Text] [Related]
47. [Antithrombotic Treatment of Pulmonary Embolism].
Ebner M; Lankeit M
Dtsch Med Wochenschr; 2020 Jul; 145(14):970-977. PubMed ID: 32668468
[TBL] [Abstract][Full Text] [Related]
48. VTE and anti-coagulation therapy in cancer patients.
Miyazaki Y; Sase K; Hasegawa K; Morimoto T
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):189-191. PubMed ID: 31378809
[No Abstract] [Full Text] [Related]
49. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Burness CB; Perry CM
Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
[TBL] [Abstract][Full Text] [Related]
50. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
51. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
52. [Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Kawaguchi M; Uchimura N; Okuda Y; Konuma S; Nehashi Y
Rinsho Ketsueki; 2015 Aug; 56(8):1096-9. PubMed ID: 26345573
[TBL] [Abstract][Full Text] [Related]
53. Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Howard LS
Expert Rev Respir Med; 2018 May; 12(5):387-402. PubMed ID: 29542359
[TBL] [Abstract][Full Text] [Related]
54. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
55. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P
Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350
[TBL] [Abstract][Full Text] [Related]
56. Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients.
Langella V; Bottino R; Asti A; Maresca G; Di Palma G; Pomponi D; Sassone C; Imbalzano E; Russo V
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1289-1294. PubMed ID: 34402362
[TBL] [Abstract][Full Text] [Related]
57. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report.
Nakao S; Masuda T; Sakamoto S; Yamaguchi K; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Medicine (Baltimore); 2019 Mar; 98(12):e14821. PubMed ID: 30896626
[TBL] [Abstract][Full Text] [Related]
58. Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.
Campello E; Spiezia L; Simion C; Tormene D; Camporese G; Dalla Valle F; Poretto A; Bulato C; Gavasso S; Radu CM; Simioni P
J Am Heart Assoc; 2020 Dec; 9(23):e018917. PubMed ID: 33222589
[TBL] [Abstract][Full Text] [Related]
59. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
60. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]